Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil (5-FU)

被引:83
|
作者
Kevadiya, Bhavesh D. [1 ,4 ]
Patel, Tapan A. [2 ]
Jhala, Devendrasinh D. [2 ]
Thumbar, Rahul P. [3 ]
Brahmbhatt, Harshad [1 ]
Pandya, Maharshi P. [4 ]
Rajkumar, Shalini [4 ]
Jena, Prasant K. [4 ]
Joshi, Ghanshyam V. [1 ]
Gadhia, Pankaj K. [3 ]
Tripathi, C. B. [5 ]
Bajaj, Hari C. [1 ]
机构
[1] CSIR, Discipline Inorgan Mat & Catalysis, Cent Salt & Marine Chem Res Inst, Bhavnagar 364021, Gujarat, India
[2] Gujarat Univ, Dept Zool, Univ Sch Sci, Ahmadabad, Gujarat, India
[3] Veer Narmad S Gujarat Univ, Dept Biosci, Surat, Gujarat, India
[4] Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India
[5] Govt Med Coll, Dept Pharmacol, Bhavnagar, Gujarat, India
关键词
Nanocomposites; Intercalation; Na+-clay; Controlled drug release; Genotoxicity; ADVANCED COLORECTAL-CANCER; DNA-DAMAGE; RELEASE; FLUOROURACIL; DELIVERY; THERAPY; MONTMORILLONITE; NANOPARTICLES; MECHANISMS;
D O I
10.1016/j.ejpb.2012.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report here the intercalation of 5-fluorouracil (5-FU), an anticancer drug in interlayer gallery of Na+ clay (Montmorillonite, MMT), with the assistance of biopolymer (chitosan, CS). The X-ray diffraction patterns, thermal and spectroscopic analyses indicated the drug intercalation into the clay interlayer space in support of CS and stabilized in the longitudinal monolayer by electrostatic interaction. In vitro drug release showed controlled release pattern. The genotoxic effect of drug was in vitro evaluated in human lymphocyte cell culture by comet assay, and results indicated significant reduction in DNA damage when drug was intercalated with clay and formulated in composites. The results of in vitro cell viability assay in cancer cells pointed at decreased toxicity of drug when encapsulated in Na+-clay plates than the pristine drug. In vivo pharmacokinetics, biodistribution, hepatotoxicity markers, e.g., SGPT and SGOT, and liver/testicular histology in rats showed plasma/tissue drug levels were within therapeutic window as compared to pristine drug. Therefore, drug-clay hybrid and composites can be of considerable value in chemotherapy of cancer with reduced side effects. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [21] Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrugs
    Beall, HD
    Sloan, KB
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 129 (1-2) : 203 - 210
  • [22] Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs
    Roberts, WJ
    Sloan, KB
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) : 1028 - 1036
  • [23] Inhibition of lens epithelial growth using 5-fluorouracil (5-FU)
    McCauley, MB
    Scribbick, FW
    Reitstetter, RE
    Chapa, I
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [24] SYNERGISTIC LETHAL EFFECTS OF ENDOTOXIN AND 5-FLUOROURACIL (5-FU) IN MOUSE
    NOVAK, D
    DRUMMOND, D
    MUNSON, AE
    JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY, 1973, 13 (04): : 354 - 354
  • [25] 5-FLUOROURACIL (5-FU) OINTMENT IN TREATMENT OF SKIN TUMOURS AND KERATOSES
    ALMEIDAG.JC
    NORONHA, TD
    DERMATOLOGICA, 1970, 140 : 97 - &
  • [26] CONTINUOUS 5-FLUOROURACIL (5-FU) INFUSION IN REFRACTORY CARCINOMA OF THE BREAST
    HANSEN, R
    QUEBBEMAN, E
    RITCH, P
    BEATTY, P
    ANDERSON, T
    JENKINS, D
    FRICK, J
    AUSMAN, R
    CLINICAL RESEARCH, 1986, 34 (04): : A931 - A931
  • [27] Effect of 5-fluorouracil (5-FU) infusion in myocardial perfusion scans
    Bishiniotis, T
    Mouratidou, D
    Pentheroudakis, G
    Andreadis, C
    Katseas, G
    Litos, A
    Hatseras, D
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 60 - 60
  • [28] DETERMINATION OF 5-FLUOROURACIL (5-FU) IN SERUM OF CANCER TREATED PATIENTS
    COSYNSDUYCK, MC
    DELEENHEER, AP
    VANVAERENBERGH, PM
    CLINICAL CHEMISTRY, 1975, 21 (07) : 1024 - 1024
  • [29] TREATMENT OF BASAL CELL CARCINOMA WITH 5-FLUOROURACIL (5-FU) OINTMENT
    REYMANN, F
    DERMATOLOGICA, 1970, 140 : 34 - &
  • [30] NEEDLING WITH 5-FLUOROURACIL (5-FU) AND BETAMETHASONE IN FAILING FILTERING BLEBS
    FERRARI, E
    LANZETTA, P
    VIRGIL, G
    MENCHINI, U
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S85 - S85